Rockline Wealth Management LLC Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Rockline Wealth Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,611 shares of the company’s stock after buying an additional 808 shares during the period. Johnson & Johnson comprises 1.2% of Rockline Wealth Management LLC’s portfolio, making the stock its 21st largest holding. Rockline Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,036,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Harfst & Associates Inc. grew its position in shares of Johnson & Johnson by 2.5% during the 2nd quarter. Harfst & Associates Inc. now owns 12,936 shares of the company’s stock valued at $1,891,000 after acquiring an additional 318 shares during the period. Verus Capital Partners LLC grew its holdings in Johnson & Johnson by 27.2% during the second quarter. Verus Capital Partners LLC now owns 7,244 shares of the company’s stock valued at $1,059,000 after purchasing an additional 1,551 shares during the period. Convergence Investment Partners LLC increased its position in Johnson & Johnson by 54.5% in the second quarter. Convergence Investment Partners LLC now owns 13,811 shares of the company’s stock worth $2,019,000 after buying an additional 4,871 shares in the last quarter. Primoris Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 0.6% in the second quarter. Primoris Wealth Advisors LLC now owns 13,035 shares of the company’s stock worth $1,905,000 after buying an additional 76 shares during the period. Finally, DDD Partners LLC grew its stake in shares of Johnson & Johnson by 0.3% during the 2nd quarter. DDD Partners LLC now owns 124,666 shares of the company’s stock valued at $18,221,000 after acquiring an additional 396 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Sanford C. Bernstein raised their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.8 %

Shares of JNJ opened at $167.16 on Wednesday. The business’s 50 day simple moving average is $156.42 and its 200-day simple moving average is $153.60. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $167.81. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market capitalization of $402.30 billion, a price-to-earnings ratio of 10.42, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter last year, the business earned $2.80 earnings per share. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. As a group, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.